Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 4/20 | 0.68 |
| ▸ | AR | P10275 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 8/20 | 0.50 |
| ▸ | NPC1 | O15118 | 7/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6454606 | 0.96 | F10 (0.63) | F10ARKMT2AMEN1LMNA | |
| SCHEMBL6455314 | 0.84 | F10 (0.55) | F10ARKMT2AMEN1MAPK1 | |
| SCHEMBL6457987 | 0.83 | AR (0.59) | F10ARKMT2AMEN1LMNA | |
| SCHEMBL2570856 | 0.82 | AR (0.62) | F10ARKMT2AMEN1LMNA | |
| SCHEMBL24414733 | 0.81 | AR (0.70) | F10ARKMT2AMEN1LMNA | |
| SCHEMBL6459985 | 0.81 | F10 (1.00) | F10ARKMT2AMEN1MAPT | |
| SCHEMBL6461381 | 0.80 | AR (0.55) | F10ARKMT2ALMNAMAPK1 | |
| SCHEMBL24414766 | 0.79 | AR (0.67) | F10ARKMT2AMEN1LMNA | |
| SCHEMBL3423791 | 0.79 | F10 (0.86) | F10ARKMT2AMEN1LMNA | |
| SCHEMBL6460054 | 0.79 | F10 (0.64) | F10KMT2ALMNAMAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005111013-A1 | SUBSTITUTED THIOPHENE-2-CARBOXYLIC ACID AMIDES, THE PRODUCTION THEREOF AND THE USE THEREOF AS DRUGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256107-A1 | New substituted thiophene carboxamides, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256107-A1 | New substituted thiophene carboxamides, process for their preparation and their use as medicaments | OTC, TPMT, ABCG2 | F10 1901/4885AR 3491/4885KMT2A 2674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.